Clinical trial · Interventional
Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc )
STREAMLoc- Streamlined Localization Using SCOUT® at Biopsy: An Analysis of Process Improvement, Cost Savings and Enhanced Patient Experience.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sponsor decision.
Summary
Brief summary (as posted)
This registry is intended to demonstrate the utility of SCOUT® in the Canadian public and US healthcare systems with fixed resources and a conservative approach to patient and clinician exposure to harm. The efficacy and safety of this system will be further assessed, as well as the acceptance of clinicians and patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Receives SCOUT at biopsy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Device
- description
- Receives SCOUT at biopsy
- interventionNames
- Device: Receives SCOUT at biopsy
Primary outcomes (1)
- measure
- Number of Participants Invasive Visits
- timeFrame
- through study completion, an average of 6 months
- description
- Number of visits to the breast centre for an invasive procedure between biopsy and surgery
Secondary outcomes (2)
- measure
- Number of Participants With Adverse Events
- timeFrame
- through study completion; an average of 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Woman \>18 years and \< 80 years of age; 2. Classified as Breast Imaging Reporting and Data System (BI-RADS) 4C or 5; 3. Lesion depth is \< 6 cm from skin surface; 4. Non-palpable lesions; 5. Informed consent obtained. Exclusion Criteria: 1. Multicentric breast cancer; 2. Pregnant or lactating; 3. Known or suspected nickel-titanium allergy.
References
Publications (0)
Data not yet available